Clinical Trials Logo

Cytomegalovirus Infections clinical trials

View clinical trials related to Cytomegalovirus Infections.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06263218 Enrolling by invitation - CMV Infection Clinical Trials

Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil

Start date: October 1, 2023
Phase:
Study type: Observational [Patient Registry]

This is a single-center, non-interventional, retrospective study of data, at the level of the individual without identification, extracted from medical records of adult patients undergoing a kidney transplant procedure after 1st from January 2018 until reaching the sample size enrollment (around 500 individuals); this refers to the period of verification of individuals' eligibility for entry into the study. Individuals under strategy preemptive patients who developed CMV infection/disease within 12 months after transplantation. The data will be collected from date of transplant (including pre-transplant clinical history) until completion of at least 12 months after transplantation, or until graft loss, or recipient death or loss to follow-up, when/if applicable.

NCT ID: NCT05656599 Enrolling by invitation - Clinical trials for Hematopoietic Stem Cell Transplantation

Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies

Start date: January 3, 2023
Phase:
Study type: Observational

Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). The course and outcome of CMV infection are different clinically, and the mechanism of CMV infection after transplantation has not been clarified. Reconstitution of cellular immunity after HSCT is a critical determinant of the control of CMV infection. Investigators will dynamically monitor the CMV-specific cellular immune reconstitution after HSCT,and analyze the clinical factors and therapy strategies affecting recovery of CMV-specific immunity during 1 year after HSCT.

NCT ID: NCT04975893 Enrolling by invitation - Clinical trials for Cytomegalovirus Infection

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

Start date: June 18, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of the extension phase of this study is to evaluate the longer-term immune persistence of mRNA-1647 vaccine administered to CMV-seronegative and CMV-seropositive adults who completed Study mRNA-1647-P202 (NCT04232280). For participants in the optional booster phase (BP), the main purpose is to evaluate the long-term immunogenicity and safety of the mRNA-1647 vaccine in both participants receiving a booster dose (BD) and those not receiving a BD, and to additionally evaluate the reactogenicity in participants receiving a BD.

NCT ID: NCT04392297 Enrolling by invitation - CMV Clinical Trials

Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals

Start date: July 1, 2019
Phase:
Study type: Observational

Current study evaluates possible correlations between the content of various cell populations, the genetic material of the virus and antibodies to it in the blood of patients and the risk of thrombosis development in patients with acute CMV infection. А new method for the early detection of immunological and clinical signs of thromboembolic complications of CMV infection in immunocompetent individuals and the treatment of patients in this category will be developed.

NCT ID: NCT03806764 Enrolling by invitation - Clinical trials for Cytomegalovirus Infections

Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient

CReSCT
Start date: April 17, 2018
Phase: N/A
Study type: Interventional

This study consists of two parts: 1) Part 1, a retrospective part on 250 consecutive patients following allogeneic haematopoietic stem cell transplant (allo-HSCT) at the Royal Melbourne Hospital from 2012 to 2017, inclusive, and 2) Part 2, a prospective part on 120 allo-HSCT patients from 4 sites in Australia: the Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Austin Hospital, and Westmead Hospital. In Part 1, medical records of allo-HSCT recipients will be evaluated to determine the incidence and clinical outcomes of CMV viremia post HSCT, including both the direct (CMV disease) and indirect (such as invasive fungal infection, other viral infections, bacterial infection) effects on clinical outcomes. In Part 2, allo-HSCT participants at risk of CMV disease will be assessed to determine the association of host CMV-specific immunity with clinical management and outcomes over one year post allo-HSCT. The overall aims of the study are to establish if CMV infection in allo-HSCT patients are associated with poor clinical outcomes; and whether measurement of immunological functions could provide an early indicator to identify patients at risk and appropriate timing for initiation of CMV treatment.